Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

Autor Suleiman, Jamal Google Scholar
Zingman, Barry S. Google Scholar
Diaz, Ricardo Sobhie Autor UNIFESP Google Scholar
Ramalho Madruga, Jose Valdez Google Scholar
DeJesus, Edwin Google Scholar
Slim, Jihad Google Scholar
Mak, Carmen Google Scholar
Lee, Erin Google Scholar
McCarthy, Michael C. Google Scholar
Dunkle, Lisa M. Google Scholar
Walmsley, Sharon Google Scholar
Instituição Schering Plough Res Inst
Brasilmed Assistencia Med & Pesquisas
Universidade Federal de São Paulo (UNIFESP)
Ctr Referencia & Treinamento DST AIDS
Montefiore Med Ctr
Einstein Montefiore Ctr AIDS Res
Orlando Immunol Ctr
St Michaels Med Ctr Infect Dis
Univ Hlth Network
Resumo Background. Agents that block the CCR5 coreceptor for human immunodeficiency virus (HIV) have demonstrated potent antiretroviral activity. in early clinical studies, the CCR5 antagonist vicriviroc proved to be a safe and effective component of combination antiretroviral therapy.Methods. This double-blind, dose-ranging, phase 2 trial randomized subjects to receive 30 mg or 20 mg of vicriviroc or placebo once daily plus re-optimized background therapy containing a protease inhibitor with ritonavir. Subjects were adults infected with CCR5-tropic HIV who were experiencing failure of triple antiretroviral regimens. the primary end point was mean change in baseline log 10 HIV RNA level at 48 weeks, based on an intent-to-treat analysis.Results. One hundred fourteen persons received vicriviroc at 30 mg (n = 39), vicriviroc at 20 mg (n = 40), or placebo (n = 35). the mean change in baseline HIV RNA level at week 48 was -1.77 log(10) copies/mL for 30 mg of vicriviroc and -1.75 log(10) copies/mL for 20 mg of vicriviroc, compared with -0.79 log(10) copies/mL for placebo (P = .002 and P = .003, respectively, compared with placebo). Mean CD4 counts increased by 102, 136, and 63 cells/mm(3) for 30 mg vicriviroc, 20 mg vicriviroc, and placebo, respectively (P = .260 and P = .039, respectively, compared with placebo). Rates of adverse events (mostly mild-to-moderate) were 111.4, 112.5, and 147.4 events per 100 subject-years, respectively.Conclusions. Vicriviroc administered with a protease inhibitor plus ritonavir-containing regimen shows potent antiretroviral and immunologic activity sustained over 48 weeks in treatment-experienced patients.
Idioma Inglês
Financiador National Institutes of Health
Número do financiamento National Institutes of Health: AI-51519
Data 2010-02-15
Publicado em Journal of Infectious Diseases. Chicago: Univ Chicago Press, v. 201, n. 4, p. 590-599, 2010.
ISSN 0022-1899 (Sherpa/Romeo, fator de impacto)
Editor Univ Chicago Press
Extensão 590-599
Fonte http://dx.doi.org/10.1086/650342
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000273843900016
URI http://repositorio.unifesp.br/handle/11600/32270

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)

Buscar DSpace


Navegar

Minha conta